| Ytd | 147.83% | |
| 1y | 137.50% |
| Open | 3.01 | Prev Close | 3.01 | Low | 2.83 | High | 3.19 | Mkt Cap | 180.56M |
| Vol | 773.19K | Avg Vol | 761.51K | EPS | -1.30 | P/E | N/A | Forward P/E | -1.40 |
| Beta | 1.28 | Short Ratio | 3.13 | Inst. Own | 56.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.01 | 200-d Avg | 2.32 | 1yr Est | 10.00 |
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst co
Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperf
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst c
RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) wit
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO a
Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overwei
Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the p
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage compa
Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rati
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst c
On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater l
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritiz
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and
Pyxis Oncology's second clinical program, PYX-106 — a fully human IgG1 monoclonal antibody targe
RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade
TRNR: 81% | Interactive Strength Board Approves Maximum Cumulative Bitcoin Purchase Of Up To $5M; Pl
William Blair analyst Andy Hsieh downgrades Pyxis Oncology (NASDAQ:PYXS) from Outperform to Marke
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst
Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and
Stephens & Co. analyst Sudan Loganathan initiates coverage on Pyxis Oncology (NASDAQ:PYXS) wi
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and